Xianjun Yu



  1. Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, et al. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. Onco Targets Ther. 2018;11:4591-4608 pubmed publisher
    ..The current literature shows varying results on treatment efficacy and tolerability. Thus, we reviewed the published data on the use of chemotherapy in the second-line setting for the treatment of advanced pancreatic cancer. ..
  2. request reprint
    Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, et al. Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2016;48:969-979 pubmed
    ..The targeting of an individual metabolic phenotype with corresponding metabolic inhibitors is considered a promising therapeutic approach and, in combination with chemotherapy, is expected to be a novel strategy for PDA treatment. ..
  3. Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, et al. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Mol Cancer Res. 2017;15:201-212 pubmed publisher
    ..The current study uncovers the contribution of oncogenic KRAS to serum marker CA125 production through a mechanism that involves the ERK/c-Myc axis. Mol Cancer Res; 15(2); 201-12. ©2016 AACR. ..
  4. Huang Q, Zhou H, Liu C, Jin K, Fan K, Cheng H, et al. Surgical Resection for Metastatic Tumors in the Pancreas: A Single-Center Experience and Systematic Review. Ann Surg Oncol. 2019;: pubmed publisher
    ..In the conditions of RCC as the primary tumor, being asymptomatic, or negative resection margin, a better prognosis after resection can be achieved. ..
  5. Qin Y, Hu Q, Xu J, Ji S, Dai W, Liu W, et al. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Cell Commun Signal. 2019;17:30 pubmed publisher
    ..The PRMT5/FBW7/cMyc axis could be a potential therapeutic target for the treatment of pancreatic cancer. ..
  6. Hu Q, Qin Y, Ji S, Xu W, Liu W, Sun Q, et al. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Cancer Lett. 2019;452:226-236 pubmed publisher
    ..Our study identified a novel UHRF1/SIRT4 axis in regulation of pancreatic cancer cell proliferation, metabolism, and metastasis. ..
  7. Gao H, Wang W, Xu H, Wu C, Jin W, Zhang S, et al. Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. Pancreatology. 2019;19:472-477 pubmed publisher
    ..Metastatic insulinoma had worse prognosis than non-insulinoma F-PanNET. These findings may help in the clinical management of metastatic insulinoma. ..
  8. Wang W, Liu L, Xu J, Yu X. Reflections on depletion of tumor stroma in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2019;1871:267-272 pubmed publisher
    ..In-depth understanding of the critical role of the stroma in cancer metastasis may improve therapeutic approaches by allowing them to harness specific features of the stroma to treat pancreatic cancer. ..
  9. Cheng H, Fan K, Luo G, Fan Z, Yang C, Huang Q, et al. KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. Cancer Lett. 2019;446:103-111 pubmed publisher
    ..These results provide new insights into the relationship between gene mutation and immune escape. ..

More Information


  1. Meng Q, Xu J, Liang C, Liu J, Hua J, Zhang Y, et al. GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Cell Death Dis. 2018;9:1187 pubmed publisher
    ..In summary, this study increases our understanding of the role of GPx1 in the induction of protective autophagy in PDA cells under extreme glucose starvation and may provide new therapeutic targets or innovative therapies. ..
  2. Xu W, Hu Q, Qin Y, Zhang B, Liu W, Ni Q, et al. Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis via suppression of sirtuin 3 in pancreatic cancer. World J Gastroenterol. 2018;24:4893-4905 pubmed publisher
    ..ZEB1 silenced SIRT3 expression via interaction with MBD1 to promote aerobic glycolysis in pancreatic cancer. ..
  3. Jin W, Xu H, Zhang S, Li H, Wang W, Gao H, et al. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019;26:635-643 pubmed publisher
    ..NETs were an independent prognostic factor in PDAC and incorporation of NETs along with the standard TNM stating system refined risk-stratification and predicted survival in PDAC with improved accuracy. ..
  4. Zhang S, Li H, Wang W, Jin W, Xu J, Xu H, et al. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2019;45:769-775 pubmed publisher
    ..048). The Arpin level is an independent prognostic factor that can be a potential predictor to aid in the management of PDAC. ..
  5. Zhang Z, Ji S, Zhang B, Liu J, Qin Y, Xu J, et al. Role of angiogenesis in pancreatic cancer biology and therapy. Biomed Pharmacother. 2018;108:1135-1140 pubmed publisher
    ..Translational information from recent molecular biology and animal studies is also summarized. Finally, the dosing schedule for bevacizumab with other chemotherapeutic protocols for pancreatic cancer treatment is discussed. ..
  6. Zhang S, Yao L, Wang W, Xu J, Xu H, Jin W, et al. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2018;25:3984-3993 pubmed publisher
    ..7052, 0.7623, and 0.7157; AIC: 476, 386, and 1015). TIPs were an independent prognostic factor that could be incorporated into the AJCC TNM staging system to refine risk stratification and predict surgical outcomes of patients with PDAC. ..
  7. Li S, Xu H, Wu C, Wang W, Jin W, Gao H, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22:15-36 pubmed publisher
  8. Yang C, Cheng H, Zhang Y, Fan K, Luo G, Fan Z, et al. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. Cancer Immunol Immunother. 2018;67:1815-1823 pubmed publisher
    ..A high density of NKs predicts poor survival in these patients, possibly because an active inflammatory response and reduced secretion of IL-2, IFN-γ and TNF-α inhibit NK activation. ..
  9. Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, et al. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971-976 pubmed publisher
    ..03-1.64; P = 0.028). Not all Lewis (-) patients with pancreatic cancer are non-secretors of CA19-9. Contrary to general understanding, CA19-9 can retain its utility as a biomarker in these patients in spite of Lewis (-) genotype. ..
  10. Xu H, Li S, Wu C, Qi Z, Wang W, Jin W, et al. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Pancreatology. 2018;18:671-677 pubmed publisher
    ..546, 95% confidence interval: 0.352-0.847, P = 0.007 for RFS). Postoperative serum CA19-9, CA125 and CEA could serve as predictors of response for adjuvant chemoradiotherapy even if the status of lymph nodes is negative. ..
  11. Gao H, Liu L, Qi Z, Xu H, Wang W, Wu C, et al. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17:95-100 pubmed publisher
    ..37; P?=?0.001). High PD-L1 expression levels predicted a poor prognosis in PDAC patients. Thus, PD-L1 status helps determine treatment in PDAC patients. ..
  12. request reprint
    Xu Y, Lu Y, Cheng H, Jiang J, Xu J, Long J, et al. High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC. Curr Mol Med. 2015;15:360-7 pubmed
    ..In conclusion, tumor-derived HLA-G may indicate the mechanism of immune escape and impaired PDAC clinical outcome, especially in early-stage patients, which may also be a potential therapeutic target. ..
  13. Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, et al. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Lett. 2015;360:227-33 pubmed publisher
    ..Further research is needed to better understand why pancreatic cancer patients with abnormal expressions of TP53, CDKN2A/p16, and SMAD4/DPC4 get high metabolic tumor burden. ..
  14. Meng Q, Shi S, Liang C, Liang D, Hua J, Zhang B, et al. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling. Oncogene. 2018;37:5843-5857 pubmed publisher
    ..Furthermore, GPx1 may be a potential predictive biomarker in GEM-treated PDAC patients. ..
  15. Liang D, Shi S, Liang C, Meng Q, Zhang B, Ni Q, et al. Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. Surgery. 2018;163:1080-1089 pubmed publisher
    ..497-1.743]; P = .821). Mismatch repair status in pancreatic cancer patients is not only a prognostic indicator but also a potential guiding factor for the use of 5-fluorouracil-based adjuvant chemotherapy. ..
  16. Zhang Y, Yang C, Cheng H, Fan Z, Huang Q, Lu Y, et al. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. J Hematol Oncol. 2018;11:14 pubmed publisher
    ..Combination therapies of classic chemotherapeutic drugs and novel agents or novel therapeutic combinations might bring hope to the dismal prognosis for PDAC patients. ..
  17. request reprint
    Cheng H, Liu C, Cai X, Lu Y, Xu Y, Yu X. iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research. Curr Stem Cell Res Ther. 2016;11:444-50 pubmed
  18. Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, et al. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Int J Mol Sci. 2016;17: pubmed publisher
    ..Adjuvant chemotherapy and radiotherapy were significantly associated with improved survival in contrary EGFR expressing subgroup. Further studies of EGFR as a potential target for pancreatic cancer treatment are warranted. ..
  19. Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, et al. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Biochim Biophys Acta. 2016;1866:177-188 pubmed publisher
    ..Therefore, a better understanding of the metabolic features of PDA will contribute to the development of novel diagnostic and therapeutic strategies. ..
  20. Liu Z, Jin K, Guo M, Long J, Liu L, Liu C, et al. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Ann Surg Oncol. 2017;24:561-568 pubmed publisher
    ..An elevated CRP/Alb ratio is an independent factor for poor prognosis with the cutoff value of 0.180. ..
  21. Fan K, Yang C, Fan Z, Huang Q, Zhang Y, Cheng H, et al. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Cancer Lett. 2018;418:167-175 pubmed publisher
    ..These findings may provide deeper insight into potential pancreatic cancer therapy approaches. ..
  22. Xiang J, Hu Q, Qin Y, Ji S, Xu W, Liu W, et al. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Cell Death Dis. 2018;9:321 pubmed publisher
    ..In summary, we identified novel predictive markers for prognosis and suggest a previously unrecognized role for TCF7L2 in control of aerobic glycolysis in pancreatic cancer. ..
  23. Xu J, Ji S, Zhang B, Ni Q, Yu X. Strategies for pancreatic anastomosis after pancreaticoduodenectomy: What really matters?. Hepatobiliary Pancreat Dis Int. 2018;17:22-26 pubmed publisher
    ..Pancreatic surgeons should choose a suitable technique according to the characteristics of individual cases. ..
  24. Ji S, Yang W, Liu J, Zhao J, Chen L, Ni Q, et al. High throughput gene sequencing reveals altered landscape in DNA damage responses and chromatin remodeling in sporadic pancreatic neuroendocrine tumors. Pancreatology. 2018;18:318-327 pubmed publisher
    ..Our findings will prompt further studies into the role of these mutated genes in the oncogenesis and molecular stratification of PNETs. ..
  25. Wang Y, Jin K, Tan H, Zhang P, Yang Q, Wang W, et al. Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. Cancer Chemother Pharmacol. 2017;80:507-516 pubmed publisher
    ..Patients with higher sunitinib Css seem to have better efficacy. Sunitinib-related hypertension may be a predictor of a better treatment effect. ..
  26. Guo M, Luo G, Jin K, Long J, Cheng H, Lu Y, et al. Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. Int J Mol Sci. 2017;18: pubmed publisher
    ..Our study revealed an insight into the variation of the gene encoding region underlying solid-pseudopapillary neoplasm tumorigenesis. The detection of these variations might partly reflect the potential molecular mechanism. ..
  27. Gao H, Liu L, Wang W, Xu H, Jin K, Wu C, et al. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. Cancer Lett. 2018;412:188-193 pubmed publisher
    ..001). This novel risk stratification thus identified PanNET patients of different recurrent-risk. Patients with very high recurrence risk may be suitable for post-operative clinical trials investigating adjuvant treatment. ..
  28. Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, et al. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. Cell Mol Life Sci. 2018;75:1001-1012 pubmed publisher
    ..This work contributes to the development of novel and promising combination GEM-based regimens that have achieved significant survival benefits for the patients with pancreatic cancer. ..
  29. Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, et al. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. Eur J Surg Oncol. 2017;: pubmed publisher
    ..76, 95% confidence interval: 2.04 to 3.74, p < 0.001). A new scoring system based on the combination of the CA125 level with the CD4/CD8 ratio could further predict the prognosis of patients with advanced pancreatic cancer. ..
  30. Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, et al. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Cancer Lett. 2017;388:303-311 pubmed publisher
    ..Taken together, our novel findings suggest ARF6, a target of mutant Kras, may promote pancreatic cancer development by enhancing the Warburg effect. ..
  31. Luo G, Liu C, Guo M, Long J, Liu Z, Xiao Z, et al. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Cancer Lett. 2017;385:46-50 pubmed publisher
    ..71, P = 0.267; chemotherapy plus radiotherapy, HR = 0.33, P = 0.022). We conclude that CA19-9-Low&Lewis (+) pancreatic cancer is a unique subtype with special biological properties. ..
  32. Xu H, Liu L, Xiang J, Wang W, Qi Z, Wu C, et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery. 2017;161:373-384 pubmed publisher
    ..The postoperative monitoring of CEA and CA125 provided prognostic significance to the measurement of CA19-9 in pancreatic cancer after resection. ..
  33. Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, et al. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology. 2016;16:1057-1062 pubmed publisher
    ..CA19-9 can be applied as an early detector of pancreatic cancer using group dependent cut-off values. ..
  34. Cheng H, Luo G, Lu Y, Jin K, Guo M, Xu J, et al. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology. 2016;16:1080-1084 pubmed publisher
    ..High NLR levels combined with poor immune state before surgery, as measured by Tregs, are associated with an extremely poor prognosis. ..
  35. Xu J, Wang W, Zhang S, Xu H, Wu C, Qi Z, et al. Intrinsic Contact Between T and N Classifications in Resected Well-Moderately Differentiated Locoregional Pancreatic Neuroendocrine Neoplasms. Ann Surg Oncol. 2018;25:647-654 pubmed publisher
    ..A new risk model is necessary to predict patient outcomes and guide clinical practice for the prognosis of pNENs. ..
  36. Chen L, Zhou L, Zhang M, Shang L, Zhang P, Wang W, et al. Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. BMC Cancer. 2017;17:521 pubmed publisher
    ..Duodenal NENs and jejunal/ileal NENs, ampullary and non-ampullary duodenal NENs shared different characteristics. Ki-67 index of 5% might be a better threshold between grade 1 and grade 2 in SI-NENs. ..